Keywords DNA repair prostate cancer genomics cfDNA PARP inhibition reversion Introduction Prostate cancer is the second most diagnosed cancer in men globally and is responsible for significant cancer-related mortality.1 The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been transformed with the introduction of poly(ADP-ribose)-polymerase inhibition (PARPi), with phase 3 trials demonstrating survival benefit in mCRPC harboring DNA repair defects including BRCA2 or...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Gemma
Contact Gemma, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack